98 In the face of melanoma’s stubborn resistance to treatment, experts are unveiling a wave of strategies that could change the course of therapy for this aggressive skin cancer. With melanoma claiming the majority of skin cancer-related deaths, despite accounting for only 1% of cases, the clinical challenge of managing advanced melanoma remains daunting. New insights from researchers aim to tackle this issue by addressing the core mechanisms behind the disease’s resilience to even the most cutting-edge therapies. The findings were published in the journal Nature Cancer. A key factor in melanoma’s resistance to treatment lies in tumour plasticity – its ability to adapt and evolve. This versatility enables cancer cells to switch between different cellular states in response to environmental pressures, including those induced by therapy. This means that despite the initial success of treatments like BRAF inhibitors and immune checkpoint blockades, many patients eventually experience a relapse. These tumour cells can resist treatment not only through genetic mutations but also via rapid, non-genetic adaptations. Scientists have been working to decode the exact processes that drive this resistance. One of the major breakthroughs has been identifying that melanoma cells can revert to a more primitive, neural crest-like state, resembling the cells from which they originally developed. This dedifferentiation makes these cells less susceptible to therapies targeting their more differentiated, or mature, forms. The tumour microenvironment (TME) – the surrounding environment of the cancer cells – also plays a significant role in both supporting and shielding the melanoma from therapeutic assaults. The latest research highlights how certain niche signals within the TME promote the survival and resilience of resistant tumour cells. For instance, molecules such as glial cell line-derived neurotrophic factor (GDNF) have been pinpointed as contributing to the adoption of therapy-resistant states. Experts are now turning their attention towards strategies aimed at targeting these microenvironmental influences. By disrupting the supportive signals in the TME, scientists hope to prevent melanoma cells from entering their resistant states in the first place, thereby enhancing the effectiveness of existing treatments. While breakthroughs in therapies such as BRAF inhibitors combined with MEK inhibitors, and immune checkpoint blockades have improved survival rates, their long-term success is still limited by the cancer’s ability to rebound. Patients with advanced disease face a high risk of progression, with approximately 70% succumbing to the illness within five years, despite the availability of these treatments. To combat this, researchers are exploring new combination therapies. Trials are testing the effectiveness of pairing BRAF/MEK inhibitors with immune checkpoint inhibitors, which may hold the key to improving long-term outcomes. The timing and sequencing of these treatments could also be critical to preventing resistance. However, large-scale clinical trials have so far struggled to significantly improve patient outcomes. While combination therapy seems promising, optimising these regimens to outmanoeuvre melanoma’s resistance remains a work in progress. The fight against melanoma is at a critical juncture. With the disease demonstrating an ability to resist the most advanced therapies, the need for innovative approaches has never been greater. Experts are optimistic that by tackling both the tumour’s intrinsic plasticity and the external influences of its microenvironment, it may be possible to develop more effective, long-lasting treatments. In the meantime, the scientific community continues to search for new solutions. Whether through fine-tuning combination therapies or breaking the tumour’s communication with its microenvironment, the next chapter in melanoma treatment could bring the hope of more durable remission for patients worldwide.